Mild Cognitive Impairment (MCI) Teleconference Speaker Bio
James E. Galvin, MD, MPH
James Galvin is an Associate Professor in the Departments of Neurology, Psychiatry and Neurobiology, Washington University School of Medicine, St. Louis, MO.
BIOGRAPHICAL SKETCH
Dr. Galvin received his bachelor’s degree in Chemistry from New York University in 1986, his Masters of Science in Nutrition (Biochemistry) from Rutgers University in 1988, his MD from the University of Medicine and Dentistry of New Jersey in 1992 and his Masters of Public Health from St. Louis University in 2004. Following his medical internship, he trained in Neurology at Thomas Jefferson University in Philadelphia (1993-1995) and served as Chief of Neurology Resident at Medical College of Pennsylvania/Hahnemann University (1995-1996). After completing his residency, Dr. Galvin served as a NINDS fellow in Neurologic Rehabilitation at the University of Pennsylvania (1996-1997) and completed post-doctoral training at the Center for Neurodegenerative Disease Research in the Department of Pathology and Laboratory Medicine under the direction of John Q. Trojanowski, MD, PhD and Virginia M-Y Lee, PhD. During this time, he joined the faculty of MCP Hahnemann as an Assistant Professor and was the Director of Ambulatory Neurology and a member of the Dementia and Memory Disorders center. He joined the faculty of Washington University in July 2000. He is the Director of the Memory Diagnostic Center and Alzheimer Treatment Unit at Washington University, and serves in the roles of Associate Clinical Core Leader and Director of Education and Community Outreach for the Alzheimer Disease Research Center. Dr. Galvin is a member of the Steering Committee for the Alzheimer Disease Cooperative Study. He is on the Board of Directors for the Lewy Body Dementia Association and is on the Scientific Advisory Council for the American Federation for Aging Research. He has been recognized for his research efforts and excellence in Geriatric Neurology and Psychiatry by his home institution and the American Academy of Neurology. He has served as an ad hoc reviewer for the NIH and numerous clinical and scientific journals. He is on the editorial board for 3 journals and serves as an Associate Editor for Neuroscience Letters. He had published over 30 scientific papers in the area of dementia and cognitive aging, is the editor of 2 textbooks on dementia and leads numerous clinical trials investigating new therapeutics for Alzheimer disease and related disorders. His research is funded by the National Institutes of Health, American Federation for Aging Research, Longer Life Foundation, and the Alzheimer Association.